Topics:

Takeda snaps up LigoCyte for $60M

Tools

Takeda acquired LigoCyte Pharmaceuticals for $60 million, with potential future payouts that were undisclosed. The Japanese company snapped up LigoCyte's lead vaccine candidate against a notorious foodborne stomach bug called norovirus gastroenteritis. The buyout follows the launch of Takeda's new vaccine division in January. Story

Filed Under

Comments